January 20, 2022

At Asphalion we are proud to announce that we are Regulatory partners of the consortium working on the RBDCOV_EU project 🦠💉🔬!!

RBD Dimer recombinant protein vaccine against SARSCoV2 (RBDCOV) is a new Horizon Europe project led by the biotech pharmaceutical company HIPRA and funded by the Horizon Europe programme which aims at testing the efficacy, tolerability, and safety of the vaccine in children (including adolescents) and immunocompromised people against the different variants of COVID-19 using a recombinant protein. The trials will last 2.5 years.

To carry out this project, HIPRA will work with an international consortium including companies and institutions from five European countries: Spain, United Kingdom, Italy, Germany and Turkey

Have a look here for further information:





Search News & Events

  • Filter by category


Related news and events


‘RBDCOV Talks’ brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting